155 results on '"Edan, G."'
Search Results
2. Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis
3. Artificial intelligence to predict clinical disability in patients with multiple sclerosis using FLAIR MRI
4. Should spinal cord MRI be systematically performed for diagnosis and follow up of multiple sclerosis? Yes
5. SMILE: a predictive model for Scoring the severity of relapses in MultIple scLErosis
6. Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society
7. Induction or escalation therapy for patients with multiple sclerosis?
8. Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients
9. Amélioration rapide de la fonction visuelle après corticothérapie orale à forte dose chez des patients atteints de neuropathie optique inflammatoire
10. La prise en charge des poussées de sclérose en plaques en 2016
11. Epidemiology of multiple sclerosis
12. Formes cavitaires de sclérose en plaques : étude multicentrique sur vingt patients
13. Ten-year prognosis in multiple sclerosis: a better outcome in relapsing−remitting patients but not in primary progressive patients
14. L’IRM est-elle utile dans le suivi des patients atteints de sclérose en plaques ? Non
15. Survey of diagnostic and treatment practices for multiple sclerosis in Europe
16. Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis?
17. Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients
18. Les critères diagnostiques de sclérose en plaques
19. Results of a phase I study in patients suffering from secondary-progressive multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301 and a possible induction of an anti-inflammatory cytokine response
20. MGAT5 alters the severity of multiple sclerosis
21. Register-based incidence of multiple sclerosis in Brittany (north-western France), 2000–2001
22. Utilisation de la mitoxantrone dans les formes malignes inaugurales de sclérose en plaques. Étude observationnelle de 30 cas. Évaluations cliniques et IRM à un an
23. Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT
24. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage
25. HLA-DRB1*15 allele influences the later course of relapsing remitting multiple sclerosis
26. IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations
27. Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b
28. Does subthalamic nucleus stimulation induce apathy in Parkinson’s disease?
29. Only physical aspects of quality of life are significantly improved by bilateral subthalamic stimulation in Parkinson’s disease
30. A vulnerability locus to multiple sclerosis maps to 7p15 in a region syntenic to an EAE locus in the rat
31. Intercellular adhesion molecule-1: a protective haplotype against multiple sclerosis
32. A second-generation genomic screen for multiple sclerosis
33. A Web-based tool for personalized prediction of long-term disease course in patients with multiple sclerosis
34. A short and validated multiple sclerosis-specific health-related quality of life measurement for routine medical practice
35. Activité sportive et sclérose en plaques
36. De la psychométrie au handicap neuropsychologique dans la sclérose en plaques. Proposition d’une batterie de dépistage en langue française et facteurs de risque cognitifs
37. Étude observationnelle de la mitoxantrone dans les formes rémittentes actives de sclérose en plaques: suivi à long terme d’une cohorte de 100 patients consécutifs
38. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial
39. HLA-DRB1* 15 allele influences the later course of relapsing remitting multiple sclerosis
40. Immunosuppressive therapy in multiple sclerosis
41. Genetic and functional studies in multiple sclerosis patients from Martinique attest for a specific and direct role of the HLA-DR locus in the syndrome
42. Interleukin-1 receptor antagonist gene in multiple sclerosis
43. NOMAD’ MUS : création d’une cohorte française de neuro-optico-myélite aiguë de Devic et des syndromes neurologiques apparentés
44. Neuromyélite optique de Devic et patients à haut risqué : enquête rétrospective nationale
45. Sécurité, tolérance et efficacité de la pravastatine dans la sclérose en plaques rémittente - STEP : une étude pilote randomisée en double aveugle contre placebo
46. Critères clinico-radiologiques d’introduction d’un traitement de seconde ligne dans la sclérose en plaques : l’expérience de 294 patients traités par interféron suivis pendant 5 ans
47. Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management.
48. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.
49. A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.
50. Semi-automatic classification of lesion patterns in patients with clinically isolated syndrome.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.